beizray

BEIZRAY is an innovative, albumin-solubilized formulation of docetaxel, a microtubule inhibitor and antineoplastic agent in the taxoid family. Unlike conventional docetaxel products that use synthetic excipients such as polysorbate 80 or sulfobutyl ether cyclodextrin (which are associated with severe hypersensitivity reactions and fluid retention), BEIZRAY uses human-derived albumin as a solubilizing agent. This novel formulation eliminates the risk of severe allergic reactions linked to synthetic excipients and significantly improves clinical safety by reducing hematologic toxicity. BEIZRAY is indicated for the treatment of breast cancer (as monotherapy after chemotherapy failure or in combination with doxorubicin and cyclophosphamide for adjuvant therapy), non-small cell lung cancer (as monotherapy after platinum therapy failure or in combination with cisplatin for untreated advanced disease), metastatic castration-resistant prostate cancer (with prednisone), advanced gastric adenocarcinoma (with cisplatin and fluorouracil), and locally advanced squamous cell carcinoma of the head and neck (with cisplatin and fluorouracil). The drug was developed by Zhuhai Beihai Biotech Co., Ltd., approved by the US FDA on October 23, 2024, and is commercialized in the US through Zydus Lifesciences[1][3][4][5][6].

Brand names

BEIZRAY

Other names

docetaxel albumin-boundalbumin solubilized docetaxel injection